Creating vaccines synthetically has the ability to increase the speed of production.
[1] In 1986, Manuel Elkin Patarroyo created the SPf66, the first version of a synthetic vaccine for Malaria.
[1] During the H1N1 outbreak in 2009, vaccines only became available in large quantities after the peak of human infections.
Philip Dormatizer, the leader of viral vaccine research at Novartis, says they have "developed a way of chemically synthesizing virus genomes and growing them in tissue culture cells".
[2] Phase I data of UB-311, a synthetic peptide vaccine targeting amyloid beta, showed that the drug was able to generate antibodies to specific amyloid beta oligomers and fibrils with no decrease in antibody levels in patients of advanced age.